← 返回前沿论文

一种结合内脏与皮下脂肪比值和全身免疫炎症指数的两步评分模型用于预测接受 Claudin18.2 靶向 CAR-T 细胞治疗的胃癌患者细胞因子释放综合征严重程度

英文原题:A two-step scoring model incorporating visceral-to-subcutaneous fat ratio and systemic immunoinflammatory index for predicting cytokine release syndrome severity in patients with gastric cancer receiving Claudin18.2-targeted CAR-T cell therapy.

PubMed 2026/03/09(内容时间) Cancer Immunol Immunother Q1 · IF 5.8(JCR 2025)

研究概要

我们分析了全身免疫炎症指数(SII)和CT图像衍生的身体成分参数对45例接受CLDN18.2靶向CAR-T细胞治疗的晚期胃癌患者CRS严重程度的影响。

中文摘要

细胞因子释放综合征(CRS)严重影响接受嵌合抗原受体(CAR)-T细胞治疗患者的生存,其决定因素的识别仍具有挑战性。我们分析了全身免疫炎症指数(SII)和CT图像衍生的身体成分参数对45例接受CLDN18.2靶向CAR-T细胞治疗的晚期胃癌患者CRS严重程度的影响。使用基于深度学习的工具自动分割并计算基线CT上的腰围、骨骼肌指数(SMI)、骨骼肌密度(SMD)、皮下脂肪面积(SFA)、内脏脂肪面积(VFA)及VFA与SFA比值(VSR)。通过ROC分析、单因素和多因素二元logistic回归探讨SII、身体成分与CRS严重程度之间的关系。CRS 1级与2级患者在SMI、SMD、SFA和腰围方面无显著差异。CRS 2级患者的VSR和SII显著高于CRS 1级患者(P = 0.003和0.012)。ROC分析显示,VSR和SII预测CRS分级的AUC分别为0.762(0.620-0.905)和0.721(0.563-0.879)。Logistic回归分析表明,SII > 553 10 9 /L和VSR 0.21与高级别CRS显著相关(P = 0.035和0.014)。我们基于VSR和SII构建了两步评分CRS预测模型,该模型预测接受CLDN18.2靶向CAR-T细胞治疗的晚期胃癌患者高级别CRS的AUC达到0.802(0.665-0.939),为早期风险分层和临床干预提供了实用工具。

展开英文摘要原文

Cytokine release syndrome (CRS) greatly impacts survival in patients who undergo chimeric antigen receptor (CAR)-T cell therapy, and the identification of its determinants is still challenging. We analysed the impact of systemic immunoinflammatory index (SII) and body composition parameters derived from CT images on the severity of CRS in 45 patients with advanced gastric cancer treated with CLDN18.2-targeted CAR-T cells. The waist circumference, skeletal muscle index (SMI), skeletal muscle density (SMD), subcutaneous fat area (SFA), visceral fat area (VFA) and VFA-to-SFA ratio (VSR) on baseline CT were automatically segmented and calculated using a deep learning-based tool. The relationship between SII, body composition, and CRS severity was investigated by using ROC analysis, univariate and multivariate binary logistic regression. There were no significant differences in SMI, SMD, SFA and waist circumference between patients with CRS grade 1 and 2. CRS grade 2 patients exhibited significantly higher VSR and SII than patients with CRS grade 1 (P = 0.003 and 0.012, respectively). ROC analysis showed that the AUCs of VSR and SII for predicting CRS grade were 0.762 (0.620-0.905) and 0.721 (0.563-0.879), respectively. Logistic regression analysis demonstrated that SII > 553 10 9 /L and VSR 0.21 were significantly linked with high grade CRS (P = 0.035 and 0.014, respectively). We constructed a two-step scoring CRS prediction model based on VSR and SII, and the AUC of this model achieved 0.802 (0.665-0.939) for predicting high-grade CRS in advanced gastric cancer patients receiving CLDN18.2-targeted CAR-T cell therapy, providing a practical tool for early risk stratification and clinical intervention.

论文信息

作者
He M、Liu L、Chen Z、Liu Y、Liu C、Ma M、Li J、Dong B
第一作者单位
Department of Radiology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, 100142, China.China
通讯作者单位
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Early Drug Development Centre, Peking University Cancer Hospital and Institute, Beijing, 100142, China. changsongqi@bjmu.edu.cn.China
期刊
Cancer immunology, immunotherapy : CII2026 Mar 9
原文标识
PubMed 41801430 · DOI 10.1007/s00262-026-04341-y